False
September 16, 2026
2 min read
Three deaths linked to immune effector cell-associated hemophagocytic syndrome prompt Novartis to halt eight rap-cel studies
September 16, 2026
2 min read
All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group
August 31, 2026
4 min read
A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors
August 26, 2026
7 min read
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field
False